trastuzumab deruxtecan
daiichi sankyo,astrazeneca
['enhertu', 'pan-tumor']
probably the most interesting part of #asco23 to me is the potential for enhertu to be used pan-tumor. goldman projecting $12b pys!! #azn 
Bi-Weekly Biotech Updates: Public & Private Market Updates, Company Building, Financing, Exit Strategies, and Emerging Science Trends | Current: Biotech VC